These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32222677)

  • 1. Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes.
    Zhong Y; Jia C; Zhang X; Liao X; Yang B; Cong Y; Pu S; Gao C
    Eur J Med Chem; 2020 May; 194():112229. PubMed ID: 32222677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
    Najjar A; Rajabi N; Karaman R
    Curr Pharm Des; 2017; 23(16):2366-2376. PubMed ID: 28155621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer platinum (IV) prodrugs with novel modes of activity.
    Chin CF; Wong DY; Jothibasu R; Ang WH
    Curr Top Med Chem; 2011; 11(21):2602-12. PubMed ID: 22039869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in platinum chemotherapeutics.
    Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
    Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancements in platinum-based anticancer drug development: A comprehensive review of strategies, discoveries, and future perspectives.
    Sahoo D; Deb P; Basu T; Bardhan S; Patra S; Sukul PK
    Bioorg Med Chem; 2024 Oct; 112():117894. PubMed ID: 39214013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fresh platinum complexes with promising antitumor activity.
    Wang X
    Anticancer Agents Med Chem; 2010 Jun; 10(5):396-411. PubMed ID: 20545618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Platin-X series: activation, targeting, and delivery.
    Basu U; Banik B; Wen R; Pathak RK; Dhar S
    Dalton Trans; 2016 Aug; 45(33):12992-3004. PubMed ID: 27493131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosylated Platinum(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery.
    Ma J; Wang Q; Huang Z; Yang X; Nie Q; Hao W; Wang PG; Wang X
    J Med Chem; 2017 Jul; 60(13):5736-5748. PubMed ID: 28603992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.
    Johnstone TC; Suntharalingam K; Lippard SJ
    Chem Rev; 2016 Mar; 116(5):3436-86. PubMed ID: 26865551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug discovery research in in-vivo antitumor-active azolato-bridged dinuclear Pt(II) complexes].
    Komeda S
    Yakugaku Zasshi; 2012; 132(3):253-9. PubMed ID: 22382827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum-based drugs: past, present and future.
    Dilruba S; Kalayda GV
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1103-24. PubMed ID: 26886018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D
    Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
    Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
    Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Drug Delivery System for Platinum-based Anticancer Drugs.
    Gao C; Zhang Y; Chen J; Wang T; Qian Y; Yang B; Dong P; Zhang Y
    Mini Rev Med Chem; 2016; 16(11):872-91. PubMed ID: 26586124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
    Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
    Shi H; Cheng Q; Yuan S; Ding X; Liu Y
    Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
    Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Developments in the Field of Anticancer Platinum Complexes.
    Galanski MS
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):285-95. PubMed ID: 18221042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
    Xu Z; Wang Z; Yiu SM; Zhu G
    Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.